Navigation Links
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
Date:6/11/2009

COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death in children younger than five worldwide.

The Phase 3 data presented at the 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) come from seven core studies in the pediatric clinical trial program for Prevenar 13 which were conducted in France, Italy, Poland, Spain and the UK. Researchers also presented health economic models which estimated the potential public health and economic impact of Prevenar 13 -- if approved and incorporated into national immunization programs -- for the Netherlands, the UK, as well as Germany and the U.S.

"Our investigational vaccine, Prevenar 13, builds on the scientific foundation of Prevenar and is designed to provide more comprehensive protection against pneumococcal disease," says Emilio A. Emini, Ph.D., Executive Vice President, Vaccines Research and Development, Wyeth Pharmaceuticals. "These new data indicate that Prevenar 13 has the potential to provide direct coverage of the 13 most common disease-causing serotypes, including 3, 6A and 19A, which have been increasing in prevalence in many regions around the world."

Prevenar 13 includes the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) in Prevenar* (Pneumococcal Polysaccharide Conjugated Vaccine, [Adsorbed]) -- the current global standard in PD prevention in infants and young children as well as six additional serotypes (1, 3, 5, 6A, 7F and 19A) associa
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... In her thought provoking debut novel ... to a not-so-distant future faced with an Ebola pandemic that is on the cusp ... tragedy to enter the world of counterterrorism, and who continues to appear in this ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... in the neuro and pain management space join prominent academics and key investors ... Center at Harvard Medical School in Boston. , Neuro Advance Boston focuses ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new ... by researchers at the Keck Graduate Institute and its collaborators. The discovery has ... findings were published online on August 27 by Scientific Reports, an open access ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply ... risk management and resiliency practitioners with luminaries and thought leaders to advance the ... recognized for their innovations and performance excellence. At that time its principle sponsor, ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
...
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
Biology Products: